At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
PF-06882961 +2 moredrug
Likely dose
PF-06882961 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, OPEN -LABEL, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF TWO STEADY STATE DOSE LEVELS OF PF-06882961 ON THE PHARMACOKINETICS OF SINGLE ORAL DOSES OF ROSUVASTATIN AND MIDAZOLAM IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OBESITY
In Brief
A Phase 1 clinical trial evaluating PF-06882961, Rosuvastatin, and 1 other intervention for Obesity. Completed, enrolled 16 participants across 1 site.
Detailed Summary
A Phase 1 Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartDec 2020
Primary CompletionMay 2021
TodayJul 2026
First PostedNov 9, 2020
Enrollment StartDec 15, 2020
Primary CompletionMay 13, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.6 years ago
Interventions
PF-06882961drug
120 mg and 200 mg BID
Rosuvastatindrug
10 mg single dose
Midazolamdrug
2mg single dose